OBJECTIVE: To evaluate the impact of different screening intervals on screening for nasopharyngeal carcinoma (NPC). METHODS: A Markov model was constructed, based on the natural history of NPC. The 5-year mortality rate of NPC was the major measurement to evaluate the efficacies of 16 screening strategies. Parameters for the model were derived from published literature. RESULTS: Screening reduced the 5-year mortality rate for NPC by 20.4 – 43.3%, compared with the equivalent rate without screening. The 5-year mortality rate and the NPC pick-up rate with strategy A1 (annual screening) were 23.6% and 83.9%, respectively. Compared with strategy A1, strategy B1 (annual screening for seropositive subjects; biennial screening for seronegative subjects) had a similar 5-year mortality rate (24.0%) and a slightly smaller NPC pick-up rate (81.7%), but led to a 39.3% reduction in total screenings. Compared with all other strategies excluding strategy A1, strategy B1 achieved the lowest 5-year mortality rate and the largest NPC pick-up rate. CONCLUSIONS: Strategy B1 had the highest efficacy for NPC screening.
YuMCYuanJM: Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol2002; 12: 421–429.
2.
XuYFLiuWLDongJQ: Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in Cantonese. BMC Med Genet2010; 11: 161.
3.
JiaWHPanQHQinHD: A case—control and a family-based association study revealing an association between CYP2E1 polymorphisms and nasopharyngeal carcinoma risk in Cantonese. Carcinogenesis2009; 30: 2031–2036.
4.
JiaWHLuoXYFengBJ: Traditional Cantonese diet and nasopharyngeal carcinoma risk: A large-scale case—control study in Guangdong, China. BMC Cancer2010; 10: 446.
5.
JemalABrayFCenterMM: Global cancer statistics. CA Cancer J Clin2011; 61: 69–90.
6.
NgWTYauTKYungRW: Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer2005; 113: 998–1001.
YangXRDiehlSPfeifferR: Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan. Cancer Epidemiol Biomarkers Prev2005; 14: 900–905.
9.
KarrayHAyadiWFkiL: Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol2005; 75: 593–602.
10.
KimuraYSuzukiDTokunagaT: Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005. Auris Nasus Larynx2011; 38: 244–249.
11.
National Office for Cancer Prevention and Control, National Central Cancer Registry, Disease Prevention and Control Bureau, Ministry of Health: Chinese Cancer Registry Annual Report 2009. Beijing: Military Medical Science Press, 2010; pp 284–301.
12.
MousaviSMSundquistJHemminkiK: Nasopharyngeal and hypopharyngeal carcinoma risk among immigrants in Sweden. Int J Cancer2010; 127: 2888–2892.
13.
Raab-TraubN: Epstein—Barr virus in the pathogenesis of NPC. Semin Cancer Biol2002; 12: 431–441.
14.
FachirohJSchoutenTHariwiyantoB: Molecular diversity of Epstein—Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: A comparison of Indonesian, Chinese, and European subjects. J Infect Dis2004; 190: 53–62.
15.
MiddeldorpJMBrinkAAvan den BruleAJ: Pathogenic roles for Epstein—Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol2003; 45: 1–36.
16.
TangJWRohwäderEChuIM: Evaluation of Epstein—Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J Clin Virol2007; 40: 284–288.
17.
HenleGHenleW: Epstein—Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer1976; 17: 1–7.
18.
LoKWToKFHuangDP: Focus on nasopharyngeal carcinoma. Cancer Cell2004; 5: 423–428.
19.
HsuWLYuKJChienYC: Familial tendency and risk of nasopharyngeal carcinoma in Taiwan: effects of covariates on risk. Am J Epidemiol2011; 173: 292–299.
20.
MelbyeMEbbesenPLevinePH: Early primary infection and high Epstein—Barr virus antibody titers in Greenland Eskimos at high risk for nasopharyngeal carcinoma. Int J Cancer1984; 34: 619–623.
21.
ChienYCChenJYLiuMY: Serologic markers of Epstein—Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med2001; 345: 1877–1882.
22.
ZengYZhangLGLiHY: Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer1982; 29: 139–141.
23.
ZengYZhongJMLiLY: Follow-up studies on Epstein—Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology1983; 20: 190–194.
24.
CaoSMLiuZJiaWH: Fluctuations of Epstein—Barr virus serological antibodies and risk for nasopharyngeal carcinoma: A prospective screening study with a 20-year follow-up. PLoS One2011; 6: e19100.
25.
JiMFWangDKYuYL: Sustained elevation of Epstein—Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer2007; 96: 623–630.
26.
NgWTChoiCWLeeMC: Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer2010; 9: 221–228.
27.
ChenHHPrevostTCDuffySW: Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models. Br J Cancer1999; 79: 1894–1900.
28.
ChoiCWLeeMCNgWT: An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. Fam Cancer2011; 10: 133–139.
KulasingamSLMyersER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA2003; 290: 781–789.
32.
NewallATBeutelsPWoodJG: Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis2007; 7: 289–296.
33.
GoldieSJKohliMGrimaD: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst2004; 96: 604–615.
34.
ZengYPiGHDengH: Epstein—Barr virus seroepidemiology in China. AIDS Res1986; 2 (suppl 1): S7–S15.
35.
JiaWHHuangQHLiaoJ: Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China. BMC Cancer2006; 6: 178.
36.
MillerDKHomanSM: Determining transition probabilities: confusion and suggestions. Med Decis Making1994; 14: 52–58.
37.
JiangSQLiuQ: Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma. Ai Zheng2009; 28: 177–180.
38.
National Office for Cancer Prevention and Control, National Central Cancer Registry, Disease Prevention and Control Bureau, Ministry of Health: Chinese Cancer Registry Annual Report 2008. Beijing: Military Medical Science Press, 2009; pp 46–49.
39.
LohKSGohBCLuJ: Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg2006; 132: 82–85.
40.
LeeAWPoonYFFooW: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys1992; 23: 261–270.
41.
KhanfirAFrikhaMGhorbelA: Prognostic factors in metastatic nasopharyngeal carcinoma. Cancer Radiother2007; 11: 461–464.
